To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
AskQtyOrders

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

4.42a day ago
4.74a day ago
arrow

LOWER/UPPER CIRCUITS

4.33
4.77
arrow
Transgene Biotek Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 150.05%, in the last year to ₹1.04 Cr. Its sector's average revenue growth for the last fiscal year was 16.24%.
noteQuarterly Revenue,rose 70% YoY to ₹0.12 Cr. Its sector's average revenue growth YoY for the quarter was 15.5%.
notePromoter Pledges,are zero.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 15.27%
Net profit growth 5Y CAGR : %
Transgene Biotek Ltd (TBL) is engaged in manufacturing drugs for:New Drug Delivery System (NDDS)-Oral Delivery of Insulin Oral Delivery Hepatitis B Vaccine and Pegylation of Protein Drugs for Sustained Release.Biogeneries-Tacrolimus and Pegylated EPO.Human Vaccines-Meningococcal Meningitis Universal Meningococcal Meningitis Haemophilus Influenza B-Hib DTP+Hib+Hep B Combination etc.Cancer Drugs/Oncology-Multiple Myeloma Barrett's Esophageal Cancer Colon Cancer and Breast Cancer..The company also in the business segment of Diagnostics CRO Services.
personal

Grow your wealth with more research recommendations

+91